US Patent

US9301932 — Liquid pharmaceutical composition comprising nitisinone

Method of Use · Assigned to Swedish Orphan Biovitrum International AB · Expires 2033-02-28 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a liquid pharmaceutical formulation of nitisinone for oral administration to treat disorders and diseases where inhibiting 4-hydroxyphenylpyruvate dioxygenase is desirable.

USPTO Abstract

The invention concerns a liquid pharmaceutical formulation suitable for oral administration, comprising a suspension of an effective amount of micronized 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (nitisinone); and citric acid buffer having a pH in the range of 2.5 to 3.5. The formulation is useful in the treatment of disorders and diseases in which inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) is desirable, e.g. in hereditary tyrosinaemia type I.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1836 — nitisinone

Patent Metadata

Patent number
US9301932
Jurisdiction
US
Classification
Method of Use
Expires
2033-02-28
Drug substance claim
No
Drug product claim
Yes
Assignee
Swedish Orphan Biovitrum International AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.